AXSM Q1 2021 Earnings — Axsome Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

AXSMAxsome Therapeutics, Inc.

$9B

Q1 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$0

Gross Profit

$0

Operating Income

-$28M

Net Income

-$29M

EPS (Diluted)

$-0.78

QoQ Revenue Growth

NaN%

Cash Flow

Operating Cash Flow

-$27M

Free Cash Flow

-$27M

Stock-Based Comp.

$4M

Balance Sheet

Total Assets

$167M

Total Liabilities

$71M

Stockholders' Equity

$96M

Cash & Equivalents

$165M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$0	$0	—
Gross Profit	$0	$0	—
Operating Income	-$28M	-$32M	+14.3%
Net Income	-$29M	-$32M	+9.9%